- 통합연구정보
- 현재 위치우수연구성과 및 연구자소개
- 현재 위치의과학
[우수성과]박해심(아주대학교병원)
박해심(아주대학교병원 알레르기내과)
J Allergy Clin Immunol Pract. 2022 Oct;10(10):2638-2645.e3. doi: 10.1016/j.jaip.2022.06.009.Epub 2022 Jun 22.
https://pubmed.ncbi.nlm.nih.gov/35752435/
Effectiveness of Maintenance and Reliever Therapy Using Inhaled Corticosteroid-Formoterol in Asthmatics
Chungsoo Kim 1, Youngsoo Lee 2, Eunyoung Lee 3, Seng Chan You 4, Jae-Hyuk Jang 2, Rae Woong Park 5, Hae-Sim Park 6
Department of Allergy & Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea. Electronic address: hspark@ajou.ac.kr.
Affiliations
- 1Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, South Korea.
- 2Department of Allergy & Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea.
- 3Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea; Office of Biostatistics, Medical Research Collaboration Center, Ajou Research Institute for Innovative Medicine, Ajou University Medical Center, Suwon, South Korea.
- 4Department of Preventive Medicine and Public Health, Yonsei University College of Medicine, Seoul, South Korea.
- 5Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, South Korea; Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea. Electronic address: veritas@ajou.ac.kr.
- 6Department of Allergy & Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea. Electronic address: hspark@ajou.ac.kr.
Abstract
Background: Real-world evidence on the effectiveness of maintenance and reliever therapy (MART) using inhaled corticosteroids plus long-acting beta-2 agonist (ICS-LABA) is sparse.
Objective: This study aimed to evaluate the clinical effectiveness of MART (ICS-formoterol) by comparing its effectiveness with that of ICS-LABA plus as-needed short-acting beta-2 agonist (SABA) in adult asthmatics.
Methods: We retrospectively retrieved data from the medical records of the Ajou University Medical Center, Korea, to compare clinical outcomes between patients treated with MART (the MART group) and those treated with ICS-LABA plus SABA (the non-MART group). Propensity score matching was performed and hazard ratios (HRs) with 95% confidence intervals were calculated using the Cox proportional hazards model. Severe asthma exacerbation (SAEx) was the primary end point, and asthma exacerbation (AEx), hospitalization, and pneumonia were secondary end points. Corticosteroid requirement was also analyzed.
Results: After propensity score matching, the MART and the non-MART groups included 231 and 512 adult asthmatics, respectively. The risk of SAEx and AEx was significantly lower in the MART group than in the non-MART group (HR [95% CI] 0.39 [0.18-0.77] and 0.61 [0.37-0.99], respectively). There was no significant difference in hospitalization and pneumonia risk between the 2 groups (HR [95% CI] 0.88 [0.55-1.37] and 0.63 [0.03-4.51], respectively). Corticosteroid requirements were lower in the MART group than in the non-MART group (median [interquartile range], 190.0 [97.9-420.0] and 411.0 [143.0-833.0] mg/person-year, respectively; P < .01).
Conclusions: The MART strategy of ICS-formoterol was associated with lower risk of AEx and reduced corticosteroid requirement.
관련기사
천식치료는 크게 평소 천식 증상이 없어도 매일 약물을 사용하는 유지치료와 천식 증상이 나빠졌을 때 추가로 사용하는 구제치료로 나뉘며,천식 구제치료로 사용하는 흡입 스테로이드-포모테롤 제제가 천식 악화를 효과적으로 막는 것으로 밝혀 천식 치료의 가이드라인을 제시하였음.
